spacer
home > ict > autumn 2017 > on the record
PUBLICATIONS
International Clinical Trials

On the Record

Undoubtedly, precision medicine is gaining momentum.
Recent reports put the market on a growth track to reach
$65-75 billion by 2021, with an estimated average growth
rate of 10-12% (1-3). A flurry of announcements regarding
the main focus therapy area, oncology, shows that the field
is attracting a lot of research attention as well as funding.

Cases in point: the $215 million committed to the
Precision Medicine Initiative database in 2015 and
the subsequent $1.45 billion allocated to precision medicine
as part of the 21st Century Cures Act by the Obama
Administration (4). Meanwhile, China launched a five-year,
$3 billion precision medicine initiative in 2016, and the UK
has announced €300 million funding for a four-year project
to map 100,000 of people’s genomes this year (3,5).
The Swiss pharmaceutical hub of Basel – home to powerhouses
Novartis and Roche – has set up a cross-industry innovation
platform for precision medicine, and Qatar has established a
world-class genome project and biobank (6,7).

This surge of activity has been spurred by innovations
in medical technologies, such as drug discovery, companion
diagnostics, next-generation sequencing, bioinformatics
and big data analytics. These allow the diagnosis of certain
diseases based on the analysis of genetic information –
via genomics and specific biomarker techniques – and
the ability to treat particular diseases with new genetic
manipulation methods.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Clinerion'sTigran Arzumanov, PhD, MBA,
has been working in the area of Clinical
Research Sales and Marketing since
2004 and has extensive experience in
commercial aspects of both pharma
research services and eClinical solutions.

Le Vin Chin
is Head of Marketing
and Communications at Clinerion and
has been working in communications
and marketing for 20 years in a wide
variety of industries, including software
and services.
spacer
Tigran Arzumanov
spacer
spacer
spacer
Le Vin Chin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Acquires KWS BioTest

WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 11, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement